<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845127</url>
  </required_header>
  <id_info>
    <org_study_id>CIP-0080</org_study_id>
    <nct_id>NCT03845127</nct_id>
  </id_info>
  <brief_title>Randomized Evaluation and Verification of Ventricular Enhancement</brief_title>
  <acronym>REVIVE-HF</acronym>
  <official_title>Randomized Evaluation and Verification of Ventricular Enhancement: The REVIVE-HF Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioVentrix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Imaging Clinical Trial Services GmbH, Meditrial Europe Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>BioVentrix</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, multi-center, dual-arm randomized controlled study comparing treatment of
      ischemic cardiomyopathy induced heart failure with the Revivent TC System plus Guideline
      Directed Medical Therapy (GDMT) compared to GDMT alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to demonstrate that treatment with the BioVentrix Revivent TC
      System is more effective than guideline directed medical therapy for the treatment of
      ischemic heart failure. This is a prospective, multi-center, dual-arm randomized controlled
      study comparing treatment of ischemic cardiomyopathy induced heart failure with the Revivent
      TC System plus Guideline Directed Medical Therapy (GDMT) compared to GDMT alone. This study
      will include 180 patients of which 120 patients will be treated with the investigational
      device and 60 patients will be maintained on GDMT.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2:1 Randomized Study Design. Crossover permitted after 6 months.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 Minute Walking Distance</measure>
    <time_frame>3 and 6 months after enrollment</time_frame>
    <description>Improvement of heart failure symptoms compared to baseline as measured by changes in 6 Minute Walking Distance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Index</measure>
    <time_frame>3 and 6 months after enrollment</time_frame>
    <description>Changes in Quality of Life Index measured compared to baseline using the MLHFQ Quality of Life Questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Classification</measure>
    <time_frame>3 and 6 months after enrollment</time_frame>
    <description>Changes in NYHA Heart Classification compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVESVI and LVEDVI</measure>
    <time_frame>3 and 6 months after enrollment</time_frame>
    <description>Changes in left ventricular end systolic volume index (LVESVI) end diastolic volume index (LVEDVI) measured by echocardiogram compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF</measure>
    <time_frame>3 and 6 months after enrollment</time_frame>
    <description>Changes in left ventricular ejection fraction (LVEF) measured by echocardiogram compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Ischemic Cardiomyopathy</condition>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Revivent TC Ventricular Enhancement System plus GDMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive treatment with the Revivent TC Ventricular Enhancement System while being maintained on Guideline Directed Medical Therapy for treatment of Heart Failure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GDMT Only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be maintained on Guideline Directed Medical Therapy for treatment of Heart Failure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Revivent TC Ventricular Enhancement System</intervention_name>
    <description>Anchors that are implanted into the left ventricle to reshape and reduce the size and increase the efficiency of the pumping chamber.</description>
    <arm_group_label>Revivent TC Ventricular Enhancement System plus GDMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDMT</intervention_name>
    <description>Guideline Directed Medical Therapy</description>
    <arm_group_label>GDMT Only</arm_group_label>
    <arm_group_label>Revivent TC Ventricular Enhancement System plus GDMT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering from heart failure symptoms with cardiac dysfunction caused by a
             previous myocardial infarction resulting in increased LV systolic volume and in a
             discrete, contiguous, acontractile, (akinetic and/or dyskinetic) scar located in the
             antero-septal, apical (may extend laterally) region of the left ventricle.

        Exclusion Criteria:

          -  Calcified ventricular wall in the area of intended scar exclusion as verified by one
             or more appropriate imaging modalities;

          -  Inadequate myocardial viability in regions remote from the scar.

          -  Thrombus or intra-ventricular mass in the left atrium or ventricle as verified by
             echocardiography or equivalent that has not been adequately treated with weeks of
             anticoagulant at therapeutic levels;

          -  Cardiac Resynchronization Therapy (CRT) consisting of Bi-ventricular pacemaker device
             (i.e., not ICD only) placement ≤ 60 days prior to treatment;

          -  Patient intolerance or unwillingness to take anti-coagulation medication;

          -  Functioning pacemaker leads in antero-apical RV, which, in the opinion of the
             investigator, would interfere with anchor placement;

          -  Pulmonary Arterial Pressure &gt; 60 mm Hg shown by right heart catheterization to be
             precapillary or unresponsive to vasodilator therapy;

          -  Myocardial Infarction within 90 days prior to the procedure;

          -  Previous right neck surgery, previous pericardiotomy, previous left chest surgery that
             precludes device placement;

          -  Chronic renal failure with a serum creatinine &gt;2 mg/dL;

          -  Inoperable coronary disease with significant ischemia or pulmonary disease that would
             preclude transient single lung ventilation.

          -  Baseline 6-minute walk distance of &gt;450m
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Anker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Berlin-Brandenburger Centrum für Regenerative Therapien (BCRT) und Medizinische Klinik m. S. Kardiologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Volkmar Falk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ärztlicher Direktor, Direktor der Klinik für Herz-Thorax-Gefässchirurgie, Deutsches Herzzentrum Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>German Heart Institute Berlin and Charité University Medicine Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 15, 2019</study_first_submitted>
  <study_first_submitted_qc>February 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>May 29, 2020</last_update_submitted>
  <last_update_submitted_qc>May 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic Cardiomyopathy, Heart Failure, Revivent TC System</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

